| scholarly article | Q13442814 |
| P2093 | author name string | J W Bijlsma | |
| A van der Heide | |||
| A A Kruize | |||
| M J van der Veen | |||
| P2860 | cites work | The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 |
| Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update | Q28324515 | ||
| Nocardia asteroides pneumonia complicating low dose methotrexate treatment of refractory rheumatoid arthritis | Q33563859 | ||
| Cytomegalovirus pneumonia in a patient with rheumatoid arthritis treated with low dose methotrexate and prednisone | Q41232124 | ||
| Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months | Q42617960 | ||
| Cryptococcosis associated with low-dose methotrexate for arthritis. | Q54474360 | ||
| Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism | Q68094462 | ||
| Frequency of infections among rheumatoid arthritis patients, before and after disease onset | Q69198673 | ||
| Pneumocystis carinii pneumonia following methotrexate therapy for rheumatoid arthritis | Q70995225 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibiotic | Q12187 |
| patient | Q181600 | ||
| rheumatoid arthritis | Q187255 | ||
| methotrexate | Q422232 | ||
| P304 | page(s) | 224-8 | |
| P577 | publication date | 1994-04-01 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate | |
| P478 | volume | 53 |
| Q89745202 | Adverse Effects of Low-Dose Methotrexate: A Randomized Trial |
| Q33289919 | An audit of influenza and pneumococcal vaccination in rheumatology outpatients |
| Q38742606 | Anti-Toxoplasma antibodies in Egyptian rheumatoid arthritis patients |
| Q57948850 | Artritis reumatoide. manifestaciones clínicas extraarticulares. complicaciones infecciosas |
| Q33819684 | Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry |
| Q46339578 | Central Nervous System Infections Associated with Immunosuppressive Therapy for Rheumatic Disease. |
| Q24630541 | Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study |
| Q44570659 | Cytomegalovirus infection in a patient with rheumatoid arthritis |
| Q24816844 | Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study |
| Q36181137 | Do antivirals have any utility in the treatment of arthritis? |
| Q38555334 | Does methotrexate increase the risk of infection or malignancy? |
| Q34019646 | Factors associated with infection in rheumatoid arthritis |
| Q57332116 | Genetic risk factors for infection in patients with early rheumatoid arthritis |
| Q42904895 | How to reduce morbidity and mortality from chest infections in rheumatoid arthritis |
| Q35550051 | Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors |
| Q51115209 | Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis. |
| Q40478116 | Infections during low-dose methotrexate treatment in rheumatoid arthritis. |
| Q34990100 | Infections in the immunocompromised rheumatologic patient |
| Q40298171 | Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study |
| Q50614164 | Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. |
| Q36171733 | Methods to avoid infections in patients with inflammatory bowel disease |
| Q30318490 | Methotrexate toxicity. Myths and facts |
| Q37689022 | Methotrexate treatment in rheumatoid arthritis: management in clinical remission, common infection and tuberculosis. Results from a systematic literature review. |
| Q33957210 | Methotrexate use in rheumatoid arthritis. A Clinician's perspective |
| Q36300250 | No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis |
| Q38065768 | Overview of safety of non-biologic and biologic DMARDs |
| Q37662413 | Perioperative management of immunosuppression in rheumatic diseases--what to do? |
| Q41635912 | Perioperative use of methotrexate in patients with rheumatoid arthritis undergoing orthopedic surgery |
| Q38642378 | Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis. |
| Q40629895 | Predictors of infection in rheumatoid arthritis |
| Q42347671 | Reactivation of cutaneous and mucocutaneous tegumentary leishmaniasis in rheumatoid arthritis patients: an emerging problem? |
| Q35775371 | Reduced incidence of Crohn's disease in systemic sclerosis: a nationwide population study. |
| Q35759985 | Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis |
| Q40280098 | Risk factors for reported influenza and influenza-like symptoms in patients with rheumatoid arthritis |
| Q44293749 | Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide |
| Q61815016 | Risk of Infection with Methotrexate Therapy in Inflammatory Diseases: A Systematic Review and Meta-Analysis |
| Q45098990 | Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients |
| Q80080214 | Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis |
| Q35638259 | Serious infections with antirheumatic therapy: are biologicals worse? |
| Q33567058 | Severe, disseminated, life threatening herpes zoster infection in a patient with rheumatoid arthritis treated with methotrexate |
| Q33872130 | TNF-α Antagonist and Infection in Rheumatoid Arthritis. |
| Q37139401 | The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis |
| Q38267703 | Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity? |
| Q45840259 | Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort |
| Q33359987 | Urinary tract infections and lupus erythematosus |
| Q51200926 | Urinary tract infections in patients with rheumatoid arthritis. |
| Q34195402 | Validity of self-report of infections in a longitudinal cohort of patients with rheumatoid arthritis differs by source of report and infection severity |
| Q79750001 | [Bacterial osteitis. Special considerations in immunocompromised patients] |
| Q73200583 | [Bronchiectasis and rheumatoid arthritis. Incidence and etiopathogenic aspects. Review of the literature] |
| Q82719630 | [Infectious complications of biologic therapy in patients with rheumatoid arthritis] |
Search more.